GHRP-6 Research: The Hexapeptide That Led to the Ghrelin Receptor

What the published literature reports on GHRP-6: Bowers' 1984 hexapeptide, GHS-R1a and ghrelin, GH release, feeding studies in rats and GHRH comparisons.

Share

GHRP-6 is one of the historically important synthetic peptides in endocrinology. It was designed before anyone knew the receptor it acted on, and the effort to explain how it worked led to the cloning of the growth hormone secretagogue receptor and, three years later, to the discovery of ghrelin. This overview covers what the published papers report: the origin of the sequence, its pituitary and hypothalamic actions, comparisons with GHRH analogues, the rodent feeding studies, and handling points. It is written for researchers and is not a guide to any use in people.

Origin: a designed peptide, not a natural one

GHRP-6 came out of Cyril Bowers' programme with Frank Momany. In 1981, Momany, Bowers and colleagues published "Design, synthesis, and biological activity of peptides which release growth hormone in vitro" in Endocrinology, combining conformational energy calculations with synthesis to reach short peptides with GH-releasing activity. The hexapeptide itself was reported in 1984. Bowers, Momany, Reynolds and Hong described His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, then written [His1,Lys6]GHRP, in Endocrinology as eliciting a dose-related release of GH in vitro and in vivo without concomitant release of LH, FSH, TSH or PRL. It was active in rats, monkeys, lambs and calves, indicating a lack of species dependency; after intravenous injection GH rose within 2 minutes, peaked at 10 to 20 minutes and had usually returned to baseline by 2 hours. Somatostatin inhibited the response.

Structurally, the sequence is six residues, C-terminally amidated, and contains two D-amino acids (D-Trp and D-Phe). D-residues are a classic way to blunt protease recognition, part of why such a short peptide remained active in vivo.

A different receptor from GHRH

The early question was whether GHRP-6 simply hit the GHRH receptor. The published pharmacology says no.

In 1989, Cheng, Chan, Barreto, Convey and Smith reported in Endocrinology that GHRP-6 stimulated GH release from rat primary pituitary cells in a time- and dose-dependent way, and that a GRF (GHRH) antagonist did not block it, although that antagonist did shift the GRF dose-response curve. GHRP-6 did not raise intracellular cAMP, whereas GRF raised it about three-fold; together they potentiated the cAMP rise and produced synergistic GH release. The authors concluded the two act through different receptors and discrete mechanisms. The paper also reported desensitisation: pretreatment with GHRP-6 reduced the later response to GHRP-6 but not to GRF, reversing within an hour of removing the peptide.

Dickson, Leng and Robinson added the hypothalamic half in Neuroscience in 1993: systemic growth hormone-releasing peptide increased Fos expression in a subpopulation of hypothalamic neurons, and extracellular recordings showed increased firing of putative GHRH neurons in the arcuate nucleus. The compound therefore has both a pituitary and a central action.

Bowers and colleagues also published findings in people. A 1990 paper in the Journal of Clinical Endocrinology & Metabolism with Reynolds, Durham, Barrera, Pezzoli and Thorner reported GH release in normal men after intravenous GHRP, rising across the dose range tested, and synergy when submaximal GHRP was given with GHRH-(1-44)-NH2. Prolactin and cortisol rose about two-fold only at the highest dose; LH and TSH did not change over the first hour. The authors read the synergy as evidence of a physiological system not yet characterised. Doses are not reproduced here.

From orphan pharmacology to ghrelin

That system turned out to be real. In 1996, Howard and colleagues at Merck reported in Science the cloning of a G protein-coupled receptor in the pituitary and arcuate/infundibular hypothalamus of swine and humans, and showed it was the target of the growth hormone secretagogues, supporting the idea that those compounds mimic an undiscovered hormone. That receptor is GHS-R1a.

Merck had already produced a non-peptide mimic: Smith et al. reported L-692,429 in Science in 1993, describing it as a mimic of GHRP-6 acting through a signal transduction pathway distinct from GHRH's. The 1997 Endocrine Reviews article by Smith, Van der Ploeg, Howard and colleagues collects this work.

The endogenous ligand arrived in 1999, when Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa reported in Nature the purification from rat stomach of a 28-residue acylated peptide specific for GHS-R, named ghrelin, with n-octanoylation at serine 3 essential for activity. GHRP-6 is now routinely called a GHS-R1a (ghrelin receptor) agonist, a label that post-dates the peptide by fifteen years.

Feeding studies in rodents

Because GHS-R1a is the ghrelin receptor, GHRP-6 appears in the feeding literature as well.

Locke, Kirgis, Bowers and Abdoh reported in Life Sciences in 1995 that intracerebroventricular GHRP-6 in sated adult male Sprague-Dawley rats produced a near-linear, statistically significant dose-response relationship with the incidence of eating, while the change in plasma GH over the following hour was not dose-related. They concluded that the eating response occurred by a mechanism independent of GH release.

Johnstone, Srisawat, Kumarnsit and Leng followed this in Stress in 2005 using chronic i.c.v. infusion. Ad libitum fed rats given GHRP-6 increased food intake and body weight over six days, yet arcuate NPY mRNA at the end of that period was no different from controls, and in food-restricted rats GHRP-6 did not raise NPY mRNA above vehicle. CRF mRNA in the paraventricular nucleus rose with GHRP-6 in ad libitum fed rats only. A behavioural effect and a transcriptional marker need not move together. Both studies used central administration in rats and describe those models only.

Comparison with GHRH analogues

Researchers often set GHRP-6 beside GHRH analogues such as tesamorelin or CJC-1295. The distinction is mechanistic: GHRH analogues act at the GHRH receptor through a cAMP-dependent pathway, while GHRP-6 acts at GHS-R1a without raising cAMP. The two classes synergise, which is why they are studied in combination rather than as substitutes. Selectivity depends on exposure and model: the 1984 rat work found no change in LH, FSH, TSH or PRL, while the human study above reported prolactin and cortisol rising at the highest dose. Tie any selectivity claim to a specific paper.

Stability and handling notes

GHRP-6 is a short, amidated peptide containing lysine, histidine and two tryptophan residues. Lai and Topp's 1999 review in the Journal of Pharmaceutical Sciences lists oxidation, deamidation, peptide bond cleavage, the Maillard reaction and aggregation as reactions that continue in solid-state formulations, governed by temperature, moisture content and excipients. Standard practice follows: keep lyophilized material cold, dry, sealed and protected from light, let vials warm before opening, and confirm identity and purity on receipt. Our storage guide and degradation pathways article go into detail.

Because GHRP-6, GHRP-2 and hexarelin are related sequences, check the sequence and measured mass on the certificate of analysis against the published structure before comparing results with the papers above.

FAQ

What is the GHRP-6 sequence? His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (Bowers et al., 1984).

Is GHRP-6 the same as ghrelin? No. Ghrelin is a 28-residue acylated peptide isolated from rat stomach in 1999; GHRP-6 is a synthetic hexapeptide designed fifteen years earlier that acts at the same receptor.

Does GHRP-6 work through the GHRH receptor? Published pharmacology says no: a GRF antagonist did not block its effect, it did not raise cAMP, and the two act synergistically.

References

  • Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology. 1981;108(1):31-39. PMID: 6109621. doi:10.1210/endo-108-1-31.
  • Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6714155. doi:10.1210/endo-114-5-1537.
  • Cheng K, Chan WW, Barreto A, Convey EM, Smith RG. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology. 1989;124(6):2791-2798. PMID: 2541999. doi:10.1210/endo-124-6-2791.
  • Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism. 1990;70(4):975-982. PMID: 2108187. doi:10.1210/jcem-70-4-975.
  • Dickson SL, Leng G, Robinson IC. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience. 1993;53(2):303-306. PMID: 8492908. doi:10.1016/0306-4522(93)90197-n.
  • Smith RG, Cheng K, Schoen WR, et al. A nonpeptidyl growth hormone secretagogue. Science. 1993;260(5114):1640-1643. PMID: 8503009. doi:10.1126/science.8503009.
  • Locke W, Kirgis HD, Bowers CY, Abdoh AA. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sciences. 1995;56(16):1347-1352. PMID: 8614257. doi:10.1016/0024-3205(95)00087-9.
  • Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8688086. doi:10.1126/science.273.5277.974.
  • Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews. 1997;18(5):621-645. PMID: 9331545. doi:10.1210/edrv.18.5.0316.
  • Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470. doi:10.1038/45230.
  • Johnstone LE, Srisawat R, Kumarnsit E, Leng G. Hypothalamic expression of NPY mRNA, vasopressin mRNA and CRF mRNA in response to food restriction and central administration of the orexigenic peptide GHRP-6. Stress. 2005;8(1):59-67. PMID: 16019598. doi:10.1080/10253890500095283.
  • Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. Journal of Pharmaceutical Sciences. 1999;88(5):489-500. PMID: 10229638. doi:10.1021/js980374e.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.